Blue rose reveals true RNAi colours
Wednesday, 30 March, 2005
The CSIRO has revealed that part of the technology used to develop the blue rose -- unveiled last year by Japanese giant Suntory and its subsidiary, Melbourne company Florigene -- was an RNAi technique developed by CSIRO for gene replacement in plants.
In its first commercial application in plants, the CSIRO-developed RNAi technology was used to inactivate the gene encoding the enzyme dihydroflavonol reductase (DFR) in roses. The enzyme directs the synthesis of red pigments in the flower.
An RNAi molecule which hybridises with the rose DFR gene was used to inhibit the gene's expression. Scientists then inserted Florigene's patented iris DFR gene -- which makes a lot of blue pigment - plus the delphinidin gene from pansy, a gene missing in roses, to produce a blue rose.
The blue rose has yet to gain regulatory approval before it can be commercially grown and marketed.
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
Retinal health linked to dementia risk, study shows
Researchers have discovered that the blood vessels at the back of the eye — called retinal...